CBT profiles of cabozantinib approved for advanced renal cell carcinomas

[1] Bao L, CELL BIOL TOXICOL

[2] New future of cell biology and toxicology: thinking deeper [J]. CELL BIOLOGY AND TOXICOLOGY, 2016, 32 (01) : 1 - 3

[3] Kano Y., 2016, SEMIN CELL DEV BIOL

[4] Some leopards can change their spots: potential repositioning of stem cell reprogramming compounds as anti-cancer agents [J]. CELL BIOLOGY AND TOXICOLOGY, 2016, 32 (03) : 157 - 168

[5] Receptor tyrosine kinase transmembrane domains Function, dimer structure and dimerization energetics [J]. CELL ADHESION & MIGRATION, 2010, 4 (02) : 249 - 254

[6] Characterization of V-ATPase inhibitor-induced secretion of cysteine-rich with EGF-like domains 2 [J]. CELL BIOLOGY AND TOXICOLOGY, 2014, 30 (03) : 127 - 136

[7] The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic [J]. CANCER CELL, 2015, 27 (06) : 751 - 753

[8] Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy [J]. CANCER CELL, 2015, 27 (06) : 837 - 851

[9] Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution [J]. PLOS ONE, 2015, 10 (06):

[10] Wang JH, 2015, MOL CELL, V58, P710, DOI 10.1016/j.molcel.2015.05.002

[1] Bao L, CELL BIOL TOXICOL

[2] New future of cell biology and toxicology: thinking deeper [J]. CELL BIOLOGY AND TOXICOLOGY, 2016, 32 (01) : 1 - 3

[3] Kano Y., 2016, SEMIN CELL DEV BIOL

[4] Some leopards can change their spots: potential repositioning of stem cell reprogramming compounds as anti-cancer agents [J]. CELL BIOLOGY AND TOXICOLOGY, 2016, 32 (03) : 157 - 168

[5] Receptor tyrosine kinase transmembrane domains Function, dimer structure and dimerization energetics [J]. CELL ADHESION & MIGRATION, 2010, 4 (02) : 249 - 254

[6] Characterization of V-ATPase inhibitor-induced secretion of cysteine-rich with EGF-like domains 2 [J]. CELL BIOLOGY AND TOXICOLOGY, 2014, 30 (03) : 127 - 136

[7] The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic [J]. CANCER CELL, 2015, 27 (06) : 751 - 753

[8] Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy [J]. CANCER CELL, 2015, 27 (06) : 837 - 851

[9] Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution [J]. PLOS ONE, 2015, 10 (06):

[10] Wang JH, 2015, MOL CELL, V58, P710, DOI 10.1016/j.molcel.2015.05.002